EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)

Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial

Ania M Jastreboff iD, Lee M Kaplan, Juan P Frías iD, Qiwei Wu, Yu Du, Sirel Gurbuz, Tamer Coskun, Axel Haupt, Zvonko Milicevic, Mark L Hartman, Retatrutide Phase 2 Obesity Trial Investigators

New England Journal of Medicine · 10.08.2023 · 389 (6) · 514-526

DOI: 10.1056/nejmoa2301972 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 10.08.2023. Verfasst von Ania M Jastreboff und 10 weiteren Autor:innen. Beteiligte Einrichtung: From the Departments of Medicine (Endocrinology and Metabolism) and Pediatrics (Pediatric Endocrinology), Yale University School of Medicine, New Hav…. Hauptthemen laut MEDLINE: Glucagon-Like Peptide 1, Obesity, Gastric Inhibitory Polypeptide, Receptors, Glucagon. Die Arbeit wurde bisher 1192-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide 1ObesityGastric Inhibitory PolypeptideReceptors, GlucagonAnti-Obesity AgentsAdultFemaleHumansMaleBody Mass IndexDouble-Blind MethodTreatment OutcomeWeight LossInjections, Subcutaneous

Substanzen

Glucagon-Like Peptide 1Gastric Inhibitory PolypeptideReceptors, GlucagonAnti-Obesity Agents

Autor:innen und Institutionen

  • From the Departments of Medicine (Endocrinology and Metabolism) and Pediatrics (Pediatric Endocrinology), Yale University School of Medicine, New Haven, CT (A.M.J.); the Obesity and Metabolism Institute and Department o…

ORCID-Profile: Ania M Jastreboff, Juan P Frías

Förderung

  • Eli Lilly and Company

Zitieren

APA

Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., Hartman, M. L., & Retatrutide Phase 2 Obesity Trial Investigators (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine, 389(6), 514-526. https://doi.org/10.1056/nejmoa2301972

Vancouver

Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514-526. doi:10.1056/nejmoa2301972

BibTeX
@article{Jastreboff2023,
  author = {Jastreboff, Ania M and Kaplan, Lee M and Frías, Juan P and Wu, Qiwei and Du, Yu and Gurbuz, Sirel and Coskun, Tamer and Haupt, Axel and Milicevic, Zvonko and Hartman, Mark L and Retatrutide Phase 2 Obesity Trial Investigators, Retatrutide Phase 2 Obesity Trial Investigators},
  title = {Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial},
  journal = {New England Journal of Medicine},
  year = {2023},
  volume = {389},
  number = {6},
  pages = {514--526},
  doi = {10.1056/nejmoa2301972}
}
Kostenlos starten →